REPL Live signaler | Maksimer profitt med Getagraph.com

KJøP 116967 min ago

@ $6.89

Utstedt: 14 feb 2024 @ 20:38

Avkastning: 0.87%

Forrige signal: feb 14 - 19:38

Forrige signal: Selg

Avkastning: -2.96 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	631 256
Gjennomsnittsvolum	1.14M
Markedsverdi	426.65M
EPS	$0 ( 2024-02-08 )
Neste inntjeningsdato	( $-0.860 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.20
ATR14	$0.00900 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Peeples-dyer Veleka	Buy	32 000	Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	250 000	Employee Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	83 335	Common Stock
2024-04-01	Pucci Paolo	Buy	32 000	Stock Option (right to buy)
2024-04-01	Xynos Konstantinos	Buy	26 665	Common Stock

INSIDER POWER
74.56
Last 98 transactions
Buy: 2 588 053 \| Sell: 457 936

Volum Korrelasjon

Lang: -0.17 (neutral)

Kort: -0.86 (strong negative)

Signal:(43.047) Neutral

Replimune Group Inc Korrelasjon

10 Mest positive korrelasjoner
BNIXU	0.927
CASS	0.908
ATIF	0.895
COLL	0.894
COFS	0.893
CNXC	0.893
NIU	0.888
FCBP	0.887
DRTT	0.884
BTAI	0.882

10 Mest negative korrelasjoner
MTEK	-0.873
NGMS	-0.849
CRSA	-0.842
PPBT	-0.839
RMRM	-0.833
PLMR	-0.83
SLDP	-0.828
OSMT	-0.828
MVBF	-0.821
TCRX	-0.821

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Replimune Group Inc Korrelasjon - Valuta/Råvare

-0.02
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.23
( neutral )

0.10
( neutral )

Replimune Group Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2023
Omsetning:	$0
Bruttogevinst:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2022
Omsetning:	$0
Bruttogevinst:	$-4.58M (0.00 %)
EPS:	$-2.26

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.750

Financial Reports:

No articles found.

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.